Researcher Profile

Researcher Profile

Smita Dandekar, MD

Smita Dandekar, MD

Associate Professor, Department of Pediatrics
Division of Hematology and Oncology
Scientific Program:Cancer Control
Disease Teams:
Pediatric Cancer

Research Interests

Dr. Smita Dandekar's research is focused on studying survivorship outcomes to contribute to the development of recommendations for health screening among survivors of childhood, adolescent and young adult cancer.

  • Pediatrics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Therapeutics
  • Recurrence
  • Neoplasms
  • Young Adult
  • Transplants
  • Leukemia
  • Hematopoietic Stem Cells
  • Drug Therapy
  • Mutation
  • Mortality

Clinical Trials

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib (IbranceĀ®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase
A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Recent Publications


Bamme, Y & Dandekar, S 2021, 'Metastatic high-grade neuroendocrine carcinoma of unknown primary: Successful treatment in a child with extensive bone marrow involvement', Pediatric Blood and Cancer, vol. 68, no. 9, e29149.


Horn, SR, Stoltzfus, KC, Mackley, HB, Lehrer, EJ, Zhou, S, Dandekar, SC, Fox, EJ, Rizk, EB, Trifiletti, DM, Rao, PM & Zaorsky, NG 2020, 'Long-term causes of death among pediatric patients with cancer', Cancer, vol. 126, no. 13, pp. 3102-3113.
Winkels, RM, Artrip, R, Tupinio, M, Veldheer, S, Dandekar, SC & George, DR 2020, 'Opportunities for Growth: Evaluating the Feasibility of a Community Gardening Intervention Pairing Adolescent and Young Adult Cancer Survivors with Experienced Gardeners', Journal of Adolescent and Young Adult Oncology, vol. 9, no. 1, pp. 115-119.
Bujold, KE, Dandekar, S & Barbour, M 2020, 'Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series', Journal of pediatric hematology/oncology, vol. 42, no. 4, pp. 319-321.


Dandekar, S 2017, Life after HSCT: Survivorship and long-term issues. in Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, pp. 385-401.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)